Polysubstance Use Trends
Most US overdoses now involve multiple substances, fundamentally changing the clinical picture. The session covers fentanyl-stimulant co-use (the rising 'speedball' pattern), alcohol-cocaine combinations and cocaethylene toxicity, benzodiazepine-opioid risk and the post-2024 federal scheduling debate, polysubstance overdose patterns and reversal challenges, novel detection methods for emerging combinations, and the treatment implications when patients have concurrent multi-drug use disorders. Discussion addresses xylazine-fentanyl wound care, methamphetamine-fentanyl polysubstance epidemiology, the role of naloxone for non-opioid overdose, and the urgent need for randomised trial evidence on optimal MAT strategies in polysubstance use disorder populations.
- Fentanyl-stimulant co-use
- Alcohol-cocaine combinations
- Benzo-opioid risk
- Xylazine-fentanyl wound care
- Polysubstance overdose patterns
- Detection challenges
- Naloxone for non-opioid overdose
- Treatment implications
Explore the full WCAM 2027 program
- 01Opioid Use Disorder
- 02Alcohol Use Disorder
- 03Stimulants & Polysubstance Use
- 04Behavioral Addictions
- 05Harm Reduction
- 06Medication-Assisted Treatment
- 07Recovery Support Services
- 08Prevention & Early Intervention
- 09Neuroscience of Addiction
- 10Trauma & PTSD-Related Use
- 11Adolescent Addiction
- 12Pregnancy & Addiction
- 13Co-occurring Mental Illness
- 14Tobacco & Nicotine Cessation
- 15Cannabis Use Disorder
- 16Psychedelic-Assisted Therapy
- 17Digital Therapeutics in Addiction
- 18Addiction Policy & Public Health
- 19Methadone & Buprenorphine Programs
- 20Naloxone & Overdose Prevention
- 21Recovery Housing
- 22Peer Support Specialists
- 23Addiction Medicine Training
- 24Stigma & Communication
- 25Drug Policy Reform
- 26International Drug Trends
- 27Older Adults & Addiction
- 28Veterans & Addiction
- 29Criminal Justice & Treatment
- 30Family Therapy
- 31Spirituality & Recovery
- 32Genetics of Addiction
- 34Emerging Drugs of Abuse
- 35Workforce Development